智通财经APP获悉，周五，Retension Pharmaceuticals(RTSN.US)登陆美股市场，截至发稿，该股跌超10%，报10.77美元。IPO价格为12美元。Retension Pharmaceuticals是一家美国临床阶段生物制药公司，专注于开发治疗高血压及其他心血管疾病的创新药物。公司的核心在研药物RTN-001是一款新一代磷酸二酯酶5(PDE5)抑制剂，主要针对血压未得到有效控制及难治性高血压患者，目前正开展IIb期临床试验。该药物通过增强血管中的一氧化氮信号传导，帮助血管舒张、降低血压，其全球独家开发许可来自法国制药巨头赛诺菲安万特(SNY.US)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.